ILD相关肺动脉高压的血流动力学与PDE5抑制剂治疗及生存关系:PVRI GoDeep荟萃登记分析
该研究基于PVRI GoDeep国际多中心真实世界登记数据,纳入940例血流动力学资料完整的ILD-PH患者,按肺血管阻力(PVR)分层分析生存。结果显示62%患者为PVR>5 WU的重度ILD-PH,其3年与5年生存率仅29%和18%,显著差于PVR≤5 WU者及肺动脉高压患者;PDE5抑制剂治疗在重度IIP-PH与IPF-PH中与生存改善相关,但在血流动力学损害较轻者中未见此关联。
要点
- 重度ILD-PH(PVR>5 WU)预后差,3年与5年生存率分别为29%和18%。
- PDE5抑制剂在重度IIP-PH和IPF-PH中与生存改善相关。
- PDE5抑制剂联合吸入前列环素类似物优于PDE5抑制剂单药。
核心结论
- ILD-PH总体预后很差,且与PH严重程度相关。
- 在重度IIP-PH和IPF-PH中,PDE5抑制剂治疗与生存改善相关,仍需对照试验进一步验证。
研究设计与样本
- PVRI GoDeep荟萃登记收集国际PH转诊中心PH患者的真实世界数据。
- 共34,482例患者中识别出940例血流动力学资料完整的初诊ILD-PH患者,中位年龄67岁(IQR 59-74)。
- 采用Kaplan-Meier生存分析与校正Cox比例风险模型,并考虑永生时间偏倚、敏感性分析、Heller相对风险统计及目标试验模拟框架分析。
- 生存统计在独立COMPERA登记中验证。
主要发现
- 62%的ILD-PH患者为PVR>5 WU的重度ILD-PH,3年和5年生存率分别为29%和18%,显著差于PVR≤5 WU的ILD-PH患者及肺动脉高压患者。
- 重度IPF-PH患者生存最差。
- 59%的ILD-PH患者接受PH靶向治疗,以PDE5抑制剂为主。
- PDE5抑制剂治疗在重度PH中与生存改善一致相关:IIP-PH的HR为0.537(0.370-0.781),IPF-PH为0.461(0.233-0.913),接受尼达尼布/吡非尼酮背景治疗的IIP-PH为0.435(0.215-0.8)。
- 在血流动力学损害较轻的患者中未见PDE5抑制剂与生存的关联。
关键数值与推荐
- 重度ILD-PH定义为PVR>5 Wood units(WU)。
- PDE5抑制剂在重度IIP-PH、IPF-PH及抗纤维化背景治疗的IIP-PH中的生存HR分别为0.537(0.370-0.781)、0.461(0.233-0.913)、0.435(0.215-0.8)。
- PDE5抑制剂联合吸入前列环素类似物对比单药的HR为0.341(0.205-0.566)。
临床怎么用
- 对ILD-PH患者应进行血流动力学评估,以PVR>5 WU识别重度高危人群。
- 重度IIP-PH或IPF-PH患者可考虑PDE5抑制剂治疗,联合吸入前列环素类似物可能进一步获益。
- 血流动力学损害较轻者使用PDE5抑制剂的生存获益证据不足,需个体化决策。
局限性
- 为真实世界登记数据的荟萃分析,PDE5抑制剂与生存的关联需在对照试验中进一步验证。
- 摘要未报告治疗分配方式、不良反应及登记数据完整性等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives: The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods: Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results: Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59-74] yr) were identified. A total of 62% had severe ILD-PH with PVR >5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR ⩽5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370-0.781], 0.461 [0.233-0.913], and 0.435 [0.215-0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205-0.566). Conclusions: Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.
引用
- Yogeswaran A, Hassoun PM, Saleh K, et al. Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis. Am J Respir Crit Care Med. 2025. PMID: 40772955. doi:10.1164/rccm.202412-2371OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。